Drug Trial Radar · NCT00211939
CARE-2 (Calcium Acetate [PhosLo®]/Sevelamer[Renagel®] Evaluation Study 2) for Heart Calcification in Dialysis Patients
Last checked: Nov 20, 2026Latest source record: Jan 8, 2008 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
203
Actual
Start
Jan 2005
Primary completion
Dec 2006
Study completion Mar 2007
Sponsor
- Lead sponsor
- Nabi BiopharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Sep 21, 2005
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to evaluate the effects of two phosphate binders, PhosLo and sevelamer, on heart calcification in dialysis patients. The study will use a non-invasive technique, electron beam computed tomography (CT) scanning, to measure calcium in the coronary arteries, the aortic valve, and the mitral valve.
Conditions
- Calcinosis
- Arteriosclerosis
- Hyperparathyroidism, Secondary
Interventions
calcium acetateDrug
667 mg gelcap, 2-4 t.i.d titrated to serum phosphorus level
sevelamerDrug
1-3 tablets t.i.d, titrated to serum phosphorus level
atorvastatinDrug
20 mg PO qD (in PhosLo group), or held until D60 (sevelamer group); titrate by LDL levels and liver function tests
Primary outcomes
What the sponsor says the trial is designed to measure.
- electron-beam CT coronary artery calcification AGATSTON scoreTime frame: change at 12 mo from baseline
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Texas Health Sciences Center
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.